Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Other Working Capital Changes: 2016-2025

Historic Other Working Capital Changes for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Sep 2025 value amounting to -$6.4 million.

  • Rhythm Pharmaceuticals' Other Working Capital Changes fell 6123.58% to -$6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year increase of 271.92%. This contributed to the annual value of $5.5 million for FY2024, which is 292.07% up from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Other Working Capital Changes is -$6.4 million, which was down 193.88% from $6.8 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Other Working Capital Changes ranged from a high of $6.8 million in Q2 2025 and a low of -$6.4 million during Q3 2025.
  • Its 3-year average for Other Working Capital Changes is $569,818, with a median of $615,000 in 2023.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first spiked by 3,968.32% in 2023, then plummeted by 6,123.58% in 2025.
  • Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' Other Working Capital Changes stood at $4.9 million in 2021, then tumbled by 177.08% to -$3.8 million in 2022, then slumped by 37.97% to -$5.2 million in 2023, then skyrocketed by 208.81% to $5.7 million in 2024, then plummeted by 6,123.58% to -$6.4 million in 2025.
  • Its Other Working Capital Changes stands at -$6.4 million for Q3 2025, versus $6.8 million for Q2 2025 and $3.2 million for Q1 2025.